The standard of care for PDAC is the chemotherapy combination FOLFIRINOX (folinic acid, fluorouracil, irinotecan hydrochloride, and oxaliplatin) or modified-FOLFIRINOX (mFFX [folinic acid, irinotecan, oxaliplatin followed by fluorouracil]). Researchers in this study investigated whether sintilimab, a human immunoglobin G4 monoclonal antibody that binds to PD-1 and has shown efficacy in other cancer types, could improve outcomes for patients with PDAC in the first or second line. Read more . . .